Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PLx Pharm Signs First China Licensing Deal With Lee’s Pharma For GI-safe Aspirin

This article was originally published in PharmAsia News

Executive Summary

Lee’s Pharma looks to take on Bayer’s aspirin in China by seeking an Rx indication.

You may also be interested in...

Lee's Pharmaceutical In-Licenses United Therapeutics' Pulmonary Arterial Hypertension Treatment Remodulin In China

SHANGHAI - Hong Kong-based Lee's Pharmaceutical and U.S.-based United Therapeutics signed an agreement for the distribution of United Therapeutics' pulmonary arterial hypertension treatment Remodulin (treprostinil) in China, despite a recent setback for the drug's launch in Europe

One Drug Outfit On China's Periphery Stands Out From The Crowd Through Innovation

HONG KONG - A famous ability to copy, combined with a chronic shortage of innovation, has long defined China's pharmaceutical industry

Shiseido Unveils Strategy For Returning Company To Growth In 2013

Shiseido has strategic initiatives planned for its domestic and Chinese businesses and Bare Escentuals in the U.S. following a disappointing fiscal 2012 in which the Toyko-based firm recorded a net loss of $148 million.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts